SCHEMBL16492059

SCHEMBL16492059

CCC(CC)CN1C(=O)S/C(=C\c2ccc(O)c(O)c2Br)C1=O

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.57
▸ CGAS Q8N884 3/20 0.45
▸ BAG3 O95817 1/20 0.40
▸ COMT P21964 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ AMY1A P0DUB6 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CISD1 Q9NZ45 2/20 0.37
▸ AKR1B1 P15121 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16492057 0.83 SLC2A1 (0.55) SLC2A1CGASBAG3COMTALDH1A1
SCHEMBL16492058 0.82 SLC2A1 (0.54) SLC2A1CGASBAG3COMTALDH1A1
SCHEMBL12712427 0.76 SLC2A1 (0.73) SLC2A1BAG3COMTALDH1A1MEN1
SCHEMBL12712445 0.74 SLC2A1 (0.61) SLC2A1BAG3COMTALDH1A1MEN1
SCHEMBL1613879 0.73 SLC2A1 (0.57) SLC2A1CGASBAG3COMTALDH1A1
SCHEMBL1614379 0.73 SLC2A1 (1.00) SLC2A1BAG3COMTALDH1A1MEN1
SCHEMBL1614974 0.70 SLC2A1 (0.77) SLC2A1BAG3COMTALDH1A1MEN1
SCHEMBL28814823 0.69 MEN1 (0.49) SLC2A1ALDH1A1MEN1KMT2AMAPT
SCHEMBL28814821 0.69 MEN1 (0.49) SLC2A1ALDH1A1MEN1KMT2AMAPT
SCHEMBL8182647 0.69 AKR1B1 (0.62) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9174951-B2 Glucose transporter inhibitors OHIO STATE INNOVATION FOUNDATION (US) 2015-11-03 — — US disclosed
US-20150051255-A1 GLUCOSE TRANSPORTER INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2015-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051255-A1 GLUCOSE TRANSPORTER INHIBITORS SLC2A4, SLC2A1, SLC2A2 SLC2A1 2/4885CGAS 4241/4885BAG3 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback